How Lurbinectedin Affects Blood Cell Counts
Lurbinectedin ( Zepzelca), approved for metastatic small cell lung cancer, commonly causes myelosuppression, reducing production of key blood cells. Neutrophils drop most frequently, with grade 3/4 neutropenia in 36-57% of patients across trials, often requiring dose delays or reductions.[1][2]
Neutrophil and White Blood Cell Impacts
Neutrophil counts decline rapidly after infusion, peaking at days 7-14. In the phase 3 IMpower133 trial (combined with atezolizumab), neutropenia occurred in 84% of patients, severe (grade ≥3) in 36%. White blood cell counts fall similarly, linked to bone marrow suppression from lurbinectedin's DNA-binding mechanism.[1][3]
Effects on Red Blood Cells and Hemoglobin
Anemia arises in 66-71% of patients, with grade 3/4 cases in 11-15%. Hemoglobin levels drop due to impaired erythropoiesis, typically managed with transfusions or supportive care.[1][2]
Platelet Count Changes
Thrombocytopenia affects 45-59% of patients, severe in 11-18%. Counts nadir around day 10 post-dose, increasing bleeding risk and often prompting G-CSF prophylaxis.[2][3]
Onset, Duration, and Management
Cytopenias emerge within 1-2 weeks, resolve in 1-3 weeks with holds (53% of cases). Premedication with G-CSF reduces severe neutropenia from 72% to 30%. Monitor CBC weekly during cycles.[1][4]
Comparison to Similar Drugs
Versus topotecan (another SCLC agent), lurbinectedin shows less severe neutropenia (57% vs. 70% grade ≥3) but similar anemia rates. Combination with immunotherapy amplifies risks versus monotherapy.[3][5]
Patient Risks and Monitoring
Febrile neutropenia occurs in 15-17%; infection risk rises with low neutrophils. Elderly patients (>65) face higher grade 4 events. FDA label mandates weekly labs, dose adjustments for grade 4 drops.[2][4]
Sources:
[1] FDA Zepzelca Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf
[2] Trigo et al., Lancet Oncol 2020 (IMpower133): https://pubmed.ncbi.nlm.nih.gov/32407804/
[3] Paz-Ares et al., Lancet Oncol 2020 (ATLANTIS): https://pubmed.ncbi.nlm.nih.gov/34687613/
[4] NCCN SCLC Guidelines v2.2023
[5] Drugs.com Zepzelca Side Effects: https://www.drugs.com/sfx/zepzelca-side-effects.html